Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emilumenib - Daiichi Sankyo Company

Next Previous
Drug Profile

Emilumenib - Daiichi Sankyo Company

Alternative Names: DS-1594; DS-1594b

Latest Information Update: 20 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; University of Texas M. D. Anderson Cancer Center
  • Class Alcohols; Amines; Antineoplastics; Benzene derivatives; Cyclopentanes; Fluorinated hydrocarbons; Methyl ethers; Pyridazines; Pyrimidines; Small molecules; Thiophenes
  • Mechanism of Action Menin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Precursor T-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 20 Mar 2026 Chemical structure information, chemical name, CAS number, molecular formula added.
  • 10 Dec 2022 Pharmacodynamics data from a preclinical trials in Acute myeloid leukaemia and Precursor T-cell lymphoblastic leukaemia-lymphoma presented at 64th American Society of Hematology Annual Meeting and Exposition (ASH-2022)
  • 07 Apr 2021 Daiichi Sankyo enters into research and development agreement with the University of Texas M. D. Anderson Cancer Center for DS 1594, prior to April 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top